Correction: Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial

Table 3 Hemodynamic parameters in patients with and without sepsis*

	Patients with sepsis			Patients without sepsis
Hemodynamic variable**	DEX (n = 31)	LZ (n = 32)	P value	DEX (n = 21)	LZ (n = 19)	P value
Number of days on vasoactive drugs	1 (1)	2 (2)	0.08	1.5 (2.2)	0.3 (0.9)	0.08
Average daily number of vasoactive drugs	1.1 (0.2)	1.6 (0.5)	0.004	1.6 (0.9)	1 (0)	0.2
Ever vasoactive drugs increased	26%	47%	0.08	33%	16%	0.2
Sinus bradycardia (< 60 beats/min)	13%	6%	0.4	24%	0%	0.02
Sinus tachycardia (> 100 beats/min)	81%	84%	0.7	52%	53%	1

Mean (standard deviation) unless otherwise noted
*Abbreviations: DEX, dexmedetomidine; LZ, lorazepam
** Measured during 120-hour study drug protocol, except for sinus bradycardia & sinus tachycardia, which are measured during entire study.

ISSN: 1364-8535